Handelsavisen
prelaunch
Companies Healthcare ALMS.O
AL
ALMS.O NASDAQ Pharmaceuticals

Alms.O

$28,00
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
2,4B USD
P/E
EV / Rev
272,7x
Div yield
Op margin
-3 127,6 %
ROE
-78,8 %
Net margin
-2 825,7 %
Debt / equity
Beta
52w range
Volume
Day range
Prev close
$28,25
Open
Next earnings
2026-10-28
Ex-dividend
TR 1Y
About

Alumis Inc operates in the Health Care sector, specifically within the Pharmaceuticals industry, though its specific business activity remains unclassified in the available data.

Business. Alumis Inc operates in the Health Care sector, specifically within the Pharmaceuticals industry, though its specific business activity remains unclassified in the available data.

Classification85 %
SectorHealth Care
Industry groupPharmaceuticals
Generated · model-assisted
Sell-side consensus
BUY10 analysts
9 buy1 hold0 sell
Avg 12m price target40,11

Analyst recommendations

10 analysts · consensus Buy
Buy9
Hold1
Sell0
12-month price target
40,11
Consensus of sell-side coverage.
Upcoming events
  • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
Buy
10 analysts · indicative
Ownership
JANUS HENDERSON GROUP PLC
largest disclosed fund holder
Profitability
-78,8 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning ALMS.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to ALMS.O. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Company
    • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Alumis Inc operates in the Health Care sector, specifically within the Pharmaceuticals industry, though its specific business activity remains unclassified in the available data.

    Classification85 %
    SectorHealth Care
    Industry groupPharmaceuticals
    AI synthesis
    GENERATED

    Alumis Inc maintains a conservative capital structure with zero debt, resulting in a debt-to-equity ratio of 0.0. The company holds $89.67 million in cash and equivalents against total liabilities of $110.64 million, providing a current liquidity buffer. However, the balance sheet reflects a market capitalization of $2.38 billion, which implies a price-to-book ratio of 7.9, significantly above typical mature industry norms. The high valuation multiple suggests the market is pricing in future growth or asset value not yet reflected in the tangible book value of $301.30 million.

    Profitability metrics are deeply negative, reflecting a pre-revenue or early-stage commercial profile. The company reported a net loss of $243.33 million on revenue of only $24.05 million, resulting in a return on equity of -78.8% and a return on assets of -57.6%. These figures indicate that the company is currently burning cash to fund operations, with operating cash flow at -$369.52 million. The negative EV/EBITDA of -8.72 further underscores the lack of current earnings power.

    Segment and geographic revenue breakdowns are not provided in the available data, preventing an analysis of revenue concentration or regional exposure. The absence of this data limits the ability to assess diversification risks or specific market dependencies.

    Growth trajectory analysis is constrained by the lack of historical period data. The current revenue figure of $24.05 million stands in stark contrast to the significant operating losses, suggesting that the company is in a phase of heavy investment rather than organic revenue expansion. Without historical trends, it is not possible to determine if revenue is accelerating or decelerating.

    Risk assessment indicates low liquidity risk and low dilution risk, with no immediate filing-based flags detected. The primary risk appears to be execution and commercialization, given the substantial cash burn relative to the cash on hand. The low dilution risk suggests that the company has not recently engaged in aggressive equity issuance, preserving existing shareholder value despite the losses.

    Recent observations include strong analyst sentiment, with a mean recommendation of 1.50 (Strong Buy) and a mean price target of $40.11, implying significant upside from the current market price of $28.00. The high price target range, with a high of $55.00, suggests that analysts expect a positive catalyst or successful commercialization event in the near term.

    Key takeaways
    • The company is debt-free with a strong cash position of $89.67 million, but faces significant cash burn with operating cash flow of -$369.52 million.
    • Valuation is high at a P/B of 7.9 and EV/Revenue of 272.69, indicating the market is pricing in substantial future growth potential.
    • Profitability is negative with a net loss of $243.33 million, resulting in negative ROE and ROA.
    • Analyst sentiment is strongly positive with a mean recommendation of 1.50 and a mean price target of $40.11.
    • Classification confidence is low (0.20), and specific business activities are unclassified, limiting detailed operational analysis.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Quarterly
    Annual
    QUARTERLYFiled 2026-05-14
    Q1 2026 · Quarter highlights
    Open report →

    Revenue $1.7M, −90,0% YoY; Operating income +3,1% YoY.

    Revenue$1.7M−90,0 % YoY
    Operating income-$98.4M+3,1 % YoY
    Net income-$93.1M+6,0 % YoY
    Free cash flow-$92.3M+6,0 % YoY
    EPS
    Operating cash flow-$87.1M−8,4 % YoY
    Financials
    Income statement
    Revenue$1.7M
    Gross profit
    Operating income-$98.4M
    Net income-$93.1M
    Margins
    Gross margin
    Operating margin-5652.4%
    Net margin-5344.8%
    FCF margin-5302.5%
    Balance sheet
    Total assets$671.6M
    Total liabilities$104.6M
    Total equity$567.0M
    Cash & equivalents$63.9M
    Long-term debt$0.00
    Cash flow
    Operating cash flow-$87.1M
    CapEx-$164.0k
    Free cash flow-$92.3M
    SBC
    P&L flow · revenue → net income
    Revenue $1.7MOperating costs $100.2MNet income $93.1M
    Highlights
    • Revenue $1.7M, −90,0% YoY
    • Operating income +3,1% YoY
    • Net income +6,0% YoY
    • Free cash flow +6,0% YoY
    • Net margin -5344.8%

    Valuation TTM

    Market price
    $28,00
    Market cap
    $2.38B
    Enterprise value
    $2.29B
    P/E
    Non-GAAP P/E
    EV / Revenue
    272.7x
    EV / Op income
    EV / OCF
    P / B
    7.9x
    P / Tangible book
    7.9x
    Tangible book
    $301.3M
    Net cash
    $89.7M
    Current ratio
    Debt / equity
    ROA
    -57.6%
    ROE
    -78.8%
    Cash conversion
    156.0%
    CapEx / revenue
    -7.8%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    Business relationships3 disclosed relationships · 2 types · extracted from filings & disclosures
    Customers1
    Subsidiaries2
    EX21:17c2cb6cbe0eEX21:17c2cb6cbe0eSubsidiarie97%
    EX21:6b1d284fadf2EX21:6b1d284fadf2Subsidiarie97%

    Supply chain

    Vendors → ALMS ↔ Partners → Customers · click any node to drill
    VENDORSPARTNERSCUSTOMERSALMSALMSAlms.O3 entitiesKaken Pharmaceutical CUnclassifiedJP
    1 mention in 10-K0 from corporate websites0 from news dispatches
    Updated 2026-07-04

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    -2,86
    Predicted surprise
    +0,00
    Beat probability
    45 %
    Analysts
    10
    Other metrics
    Revenue
    no estimate
    Segment revenue
    no estimate
    Margin
    no estimate
    Segment margin
    no estimate
    as of 2026-08-03 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPSno estimateno estimate-2,86
    Revenueno estimateno estimate6,9M USD
    Operating incomeno estimateno estimate-385,8M USD
    Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution10 analysts
    Strong buy6
    Buy3
    Hold1
    Sell0
    Strong sell0
    12-month price target$40,11 · Median $39,00
    Low $25,00High $55,00
    Operating income · consensus-385,8M USD
    EPS surprise
    +0,0 %
    reported vs consensus · beat
    Revenue surprise
    +246,9 %
    reported vs consensus · beat

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low$25,00
    Mean$40,11
    Median$39,00
    High$55,00
    Spot$28,00
    +43.3 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    Op Margin-3 127,6 %Bottom quartile
    Net Margin-2 825,7 %Bottom quartile
    ROE-78,8 %Bottom quartile
    Capex / Rev-7,8 %Below median
    D/E0,00Above P75
    Cash Conv1,56Above median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    Derivative transactions

    Net acquired 1 999 313 sh3 exercises · 12 grants12 insiders
    • Pangali SanamChief Legal Officer · Stock Option (Right to Buy) → Common StockDisposed 5 000 @ $5,06exercise · 2026-07-06
    • Machado PatrickDirector · Stock Option (Right to Buy) → Common StockAcquired 15 528 @ $28,14grant · 2026-06-30
    • AKKARAJU SRINIVASDirector · Stock Option (Right to Buy) → Common StockAcquired 15 528 @ $28,14grant · 2026-06-30
    • TETRAULT LYNN A.Director · Stock Option (Right to Buy) → Common StockAcquired 15 528 @ $28,14grant · 2026-06-30
    • Yao ZhengbinDirector · Stock Option (Right to Buy) → Common StockAcquired 15 528 @ $28,14grant · 2026-06-30
    • Srivastava SapnaDirector · Stock Option (Right to Buy) → Common StockAcquired 15 528 @ $28,14grant · 2026-06-30
    • Drappa JornChief Medical Officer · Stock Option (Right to Buy) → Common StockDisposed 15 535 @ $5,06exercise · 2026-05-22
    • Drappa JornChief Medical Officer · Stock Option (Right to Buy) → Common StockDisposed 11 317 @ $8,84exercise · 2026-05-22
    • Bradley Mark ChristopherChief Development Officer · Stock Option (Right to Buy) → Common StockAcquired 190 225 @ $26,31grant · 2026-01-26
    • Hardiman Roy C.Chief Business & Strategy Ofcr · Stock Option (Right to Buy) → Common StockAcquired 190 875 @ $26,31grant · 2026-01-26
    • Pangali SanamChief Legal Officer · Stock Option (Right to Buy) → Common StockAcquired 186 200 @ $26,31grant · 2026-01-26
    • Babler MartinDirector, President, CEO and Chairman · Stock Option (Right to Buy) → Common StockAcquired 745 875 @ $26,31grant · 2026-01-26
    • Schroer John R.Chief Financial Officer · Stock Option (Right to Buy) → Common StockAcquired 202 225 @ $26,31grant · 2026-01-26
    • Goldstein David MChief Scientific Officer · Stock Option (Right to Buy) → Common StockAcquired 216 675 @ $26,31grant · 2026-01-26
    • Drappa JornChief Medical Officer · Stock Option (Right to Buy) → Common StockAcquired 221 450 @ $26,31grant · 2026-01-26

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Reference data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    • Ev To Revenue
      enterprise_value / revenue
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Return On Equity
      net_income / total_equity
    • Market Cap
      market_price * shares_outstanding_diluted
    Source documents
    • Alumis Inc. Market data — financials · 2026-08-03
    • reconciler_enqueue (reconciler) on ALMS.O · 2026-08-03
    • Alumis Inc Market data — analyst estimates · 2026-08-03
    • Alumis Inc Market data — ESG · 2026-08-03
    • ALMS.O HA canonical relationships · 2026-08-03

    Ownership & reference

    Top holders

    • JANUS HENDERSON GROUP PLCInstitutional Investor · as of 2026-03-310,02 %$46M
    • Principal Global Investors (Equity)Investment Managers · as of 2026-03-310,01 %$23M
    • UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,01 %$67M
    • T. Rowe Price Associates, Inc.Investment Managers · as of 2026-03-310,01 %$0M
    • Invesco QQQ TrustFunds · as of 2026-03-310,01 %$33M
    • Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,00 %$42M
    • Charles Schwab Investment Management, Inc.Investment Managers · as of 2026-03-310,00 %$14M
    • Goldman Sachs Asset Management, L.P.Investment Managers · as of 2026-03-310,00 %$16M
    • Northern Trust Investments, Inc.Investment Managers · as of 2026-03-310,00 %$12M
    • AQR Capital Management, LLCInvestment Managers · as of 2026-03-310,00 %$3M
    • State Street Investment Management (US)Investment Managers · as of 2026-03-310,00 %$40M
    • Victory Capital Management Inc.Investment Managers · as of 2026-03-310,00 %$2M
    • American Century Investment Management, Inc.Investment Managers · as of 2026-03-310,00 %$2M
    • FMR LLCInstitutional Investor · as of 2026-03-310,00 %$21M
    • First Trust Advisors L.P.Investment Managers · as of 2026-03-310,00 %$1M
    • Wellington Management Company, LLPInvestment Managers · as of 2026-03-310,00 %$5M
    • Bank of New York Mellon CorpInstitutional Investor · as of 2026-03-310,00 %$5M
    • Vanguard Capital Management, LLCInvestment Managers · as of 2025-12-310,00 %$40M
    • Wells Fargo AdvisorsBrokerage Firms · as of 2026-03-310,00 %$2M
    • Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,00 %$5M
    • AllianceBernstein L.P.Investment Managers · as of 2026-03-310,00 %$1M
    • Dimensional Fund Advisors, L.P.Investment Managers · as of 2026-03-310,00 %$1M
    • Nuveen LLCInvestment Managers · as of 2024-12-310,00 %$0M
    • JONES FINANCIAL COMPANIES LLLPInstitutional Investor · as of 2026-03-310,00 %$0M
    • PNC Investments LLCInvestment Managers · as of 2026-03-310,00 %$0M

    Insider activity

    Net buying28 buys · 1 sellsnet $44,7M11 insiders · last 365d
    • Pangali SanamChief Legal Officer · Common StockSold 5 000 @ $28,00$140K · 2026-07-06
    • Pangali SanamChief Legal Officer · Common StockOther 5 000 @ $5,06$25K · 2026-07-06
    • Yao ZhengbinDirector · Common StockOther 3 553 · 2026-06-30
    • AKKARAJU SRINIVASDirector · Common StockOther 3 553 · 2026-06-30
    • TETRAULT LYNN A.Director · Common StockOther 3 553 · 2026-06-30
    • Machado PatrickDirector · Common StockOther 3 553 · 2026-06-30
    • Srivastava SapnaDirector · Common StockOther 3 553 · 2026-06-30
    • Drappa JornChief Medical Officer · Common StockOther 11 317 @ $8,84$100K · 2026-05-22
    • Drappa JornChief Medical Officer · Common StockOther 15 535 @ $5,06$79K · 2026-05-22
    • Tananbaum James B.Director, 10% owner · Common StockOther 680 486 · 2026-04-01
    • Tananbaum James B.Director, 10% owner · Common StockOther 1 123 337 · 2026-04-01
    • Tananbaum James B.Director, 10% owner · Common StockOther 1 176 470 · 2026-04-01
    • Foresite Capital Management VI LLC10% owner · Common StockOther 680 486 · 2026-04-01
    • Foresite Capital Management VI LLC10% owner · Common StockOther 1 123 337 · 2026-04-01
    • Foresite Labs, LLC10% owner · Common StockOther 680 486 · 2026-04-01
    • Foresite Labs, LLC10% owner · Common StockOther 1 176 470 · 2026-04-01
    • Foresite Labs, LLC10% owner · Common StockOther 1 123 337 · 2026-04-01
    • Foresite Capital Management VI LLC10% owner · Common StockOther 1 176 470 · 2026-04-01
    • AKKARAJU SRINIVASDirector · Common StockBought 588 235 @ $17,00$10,0M · 2026-01-09
    • Foresite Capital Management VI LLC10% owner · Common StockBought 117 647 @ $17,00$2,0M · 2026-01-08
    • Foresite Labs, LLC10% owner · Common StockBought 117 647 @ $17,00$2,0M · 2026-01-08
    • Tananbaum James B.Director, 10% owner · Common StockBought 294 117 @ $17,00$5,0M · 2026-01-08
    • Tananbaum James B.Director, 10% owner · Common StockBought 117 647 @ $17,00$2,0M · 2026-01-08
    • Foresite Capital Management VI LLC10% owner · Common StockBought 294 117 @ $17,00$5,0M · 2026-01-08
    • Foresite Labs, LLC10% owner · Common StockBought 294 117 @ $17,00$5,0M · 2026-01-08

    Short positioning

    6.8Mshares short-52.7% vs prior
    3.81days to cover
    78.4%short of daily vol
    3fails-to-deliver
    as of 2026-07-15 · short-interest report (free)

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    ALMS.OCanonical
    NASDAQ · USD

    Intel & risk

    PredictorBeat prob45 %Surprise+0,00Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.
    Relationship graph
    ALMS4521.TEX21:17cEX21:6b1Pharmaceutical
    This companySectorCustomersSubsidiaries

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
    2026-07-06INSIDERPangali Sanam sold 5.0k sh — Chief Legal Officer ~$140k
    2026-07-06INSIDERPangali Sanam transacted 5.0k sh — Chief Legal Officer ~$25k
    2026-07-06INSIDERPangali Sanam disposed of 5.0k sh Stock Option (Right to Buy) — Chief Legal Officer
    2026-06-30INSIDERMachado Patrick transacted 3.6k sh — Director
    2026-06-30INSIDERAKKARAJU SRINIVAS transacted 3.6k sh — Director
    2026-06-30INSIDERYao Zhengbin transacted 3.6k sh — Director
    2026-06-30INSIDERTETRAULT LYNN A. transacted 3.6k sh — Director
    2026-06-30INSIDERSrivastava Sapna transacted 3.6k sh — Director
    2026-06-30INSIDERSrivastava Sapna acquired 15.5k sh Stock Option (Right to Buy) — Director
    2026-06-30INSIDERAKKARAJU SRINIVAS acquired 15.5k sh Stock Option (Right to Buy) — Director
    2026-06-30INSIDERTETRAULT LYNN A. acquired 15.5k sh Stock Option (Right to Buy) — Director
    2026-06-30INSIDERYao Zhengbin acquired 15.5k sh Stock Option (Right to Buy) — Director
    2026-06-30INSIDERMachado Patrick acquired 15.5k sh Stock Option (Right to Buy) — Director
    2026-05-22 00:00 UTCINSIDER4 insider transactions — 2026-05 · net buy $179k 2 derivative
    2026-05-22INSIDERDrappa Jorn transacted 11.3k sh — Chief Medical Officer ~$100k
    2026-05-22INSIDERDrappa Jorn transacted 15.5k sh — Chief Medical Officer ~$79k
    2026-05-22INSIDERDrappa Jorn disposed of 15.5k sh Stock Option (Right to Buy) — Chief Medical Officer
    2026-05-22INSIDERDrappa Jorn disposed of 11.3k sh Stock Option (Right to Buy) — Chief Medical Officer
    2026-05-18FILINGDEF 14A filing →
    2026-05-14 16:11 UTCEARNINGSQuarterly results — Q1 2026 Revenue USD 1.7M · Net USD -93.1M
    2026-05-14FILING10-Q filing →
    2026-05-14FILING8-K filing →
    2026-04-01 00:00 UTCINSIDER9 insider transactions — 2026-04
    2026-04-01INSIDERTananbaum James B. transacted 680.5k sh — Director, 10% owner
    2026-04-01INSIDERTananbaum James B. transacted 1.12M sh — Director, 10% owner
    2026-04-01INSIDERTananbaum James B. transacted 1.18M sh — Director, 10% owner
    2026-04-01INSIDERForesite Capital Management VI LLC transacted 680.5k sh — 10% owner
    2026-04-01INSIDERForesite Capital Management VI LLC transacted 1.12M sh — 10% owner
    2026-04-01INSIDERForesite Labs, LLC transacted 680.5k sh — 10% owner
    2026-04-01INSIDERForesite Labs, LLC transacted 1.18M sh — 10% owner
    2026-04-01INSIDERForesite Labs, LLC transacted 1.12M sh — 10% owner
    2026-04-01INSIDERForesite Capital Management VI LLC transacted 1.18M sh — 10% owner
    2026-03-30FILINGFORM 8-K →
    2026-03-19 16:05 UTCEARNINGSQuarterly results — Q4 2025 Revenue USD 1.9M · Net USD -92.9M
    2026-03-19 16:05 UTCEARNINGSAnnual results — FY 2026 Revenue USD 24.1M · Net USD -243.3M
    2026-03-19FILING10-K filing →
    2026-03-19FILING8-K filing →
    2026-01-26 00:00 UTCINSIDER14 insider transactions — 2026-01 · net buy $31.0M 7 derivative
    2026-01-26INSIDERBradley Mark Christopher acquired 190.2k sh Stock Option (Right to Buy) — Chief Development Officer
    Showing the 40 most recent of 69 entries.
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Reference data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage